Supernus Pharmaceuticals Price to Free Cash Flow Ratio 2012-2026 | SUPN
Historical price to free cash flow ratio values for Supernus Pharmaceuticals (SUPN) since 2012.
| Supernus Pharmaceuticals Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-06-18 | 44.38 | 94.51 | |
| 2026-03-31 | 51.69 | $0.47 | 110.07 |
| 2025-09-30 | 47.79 | $1.26 | 37.88 |
| 2025-06-30 | 31.52 | $3.30 | 9.56 |
| 2025-03-31 | 32.75 | $2.92 | 11.23 |
| 2024-12-31 | 36.16 | $3.06 | 11.82 |
| 2024-09-30 | 31.18 | $3.06 | 10.19 |
| 2024-06-30 | 26.75 | $2.77 | 9.67 |
| 2024-03-31 | 34.11 | $1.90 | 18.00 |
| 2023-12-31 | 28.94 | $1.99 | 14.53 |
| 2023-09-30 | 27.57 | $1.47 | 18.71 |
| 2023-06-30 | 30.06 | $1.21 | 24.83 |
| 2023-03-31 | 36.23 | $2.61 | 13.86 |
| 2022-12-31 | 35.67 | $1.89 | 18.90 |
| 2022-09-30 | 33.85 | $2.51 | 13.49 |
| 2022-06-30 | 28.92 | $2.05 | 14.08 |
| 2022-03-31 | 32.32 | $1.73 | 18.73 |
| 2021-12-31 | 29.16 | $2.30 | 12.67 |
| 2021-09-30 | 26.67 | $2.00 | 13.36 |
| 2021-06-30 | 30.79 | $2.16 | 14.27 |
| 2021-03-31 | 26.18 | $3.02 | 8.66 |
| 2020-12-31 | 25.16 | $2.51 | 10.03 |
| 2020-09-30 | 20.84 | $2.72 | 7.67 |
| 2020-06-30 | 23.75 | $3.32 | 7.16 |
| 2020-03-31 | 17.99 | $2.15 | 8.38 |
| 2019-12-31 | 23.72 | $2.63 | 9.01 |
| 2019-09-30 | 27.48 | $2.44 | 11.25 |
| 2019-06-30 | 33.09 | $2.90 | 11.42 |
| 2019-03-31 | 35.04 | $2.48 | 14.15 |
| 2018-12-31 | 33.22 | $2.37 | 14.02 |
| 2018-09-30 | 50.35 | $2.43 | 20.68 |
| 2018-06-30 | 59.85 | $2.00 | 29.90 |
| 2018-03-31 | 45.80 | $2.36 | 19.37 |
| 2017-12-31 | 39.85 | $2.11 | 18.86 |
| 2017-09-30 | 40.00 | $1.92 | 20.87 |
| 2017-06-30 | 43.10 | $1.74 | 24.81 |
| 2017-03-31 | 31.30 | $1.58 | 19.87 |
| 2016-12-31 | 25.25 | $1.26 | 20.02 |
| 2016-09-30 | 24.73 | $1.16 | 21.40 |
| 2016-06-30 | 20.37 | $0.65 | 31.27 |
| 2016-03-31 | 15.25 | $0.58 | 26.43 |
| 2015-12-31 | 13.44 | $0.63 | 21.21 |
| 2015-09-30 | 14.03 | $0.39 | 35.67 |
| 2015-06-30 | 16.98 | $0.26 | 65.74 |
| 2015-03-31 | 12.09 | $-0.13 | 0.00 |
| 2014-12-31 | 8.30 | $-0.59 | 0.00 |
| 2014-09-30 | 8.69 | $-0.99 | 0.00 |
| 2014-06-30 | 10.95 | $-1.39 | 0.00 |
| 2014-03-31 | 8.94 | $-1.77 | 0.00 |
| 2013-12-31 | 7.54 | $-1.87 | 0.00 |
| 2013-09-30 | 7.33 | $-3.07 | 0.00 |
| 2013-06-30 | 6.43 | $-2.67 | 0.00 |
| 2013-03-31 | 5.62 | $-3.32 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.918B | $0.719B |
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |